Association Between Use of Anticancer Drugs and Cardiovascular Disease–Related Hospitalization in Metastatic Colorectal Cancer: Insights From a Population-Based Study, the Anticancer Vigilance of Cardiac Events Study. Issue 3 (23rd September 2020)

• Record Type: Journal Article
• Authors: Dolladille, Charles; Launoy, Guy; Bouvier, Véronique; Salem, Joe-Elie; Legallois, Damien; Milliez, Paul; Sassier, Marion; Lobbedez, Thierry; Guittet, Lydia; Alexandre, Joachim
• Is Part Of: American journal of epidemiology. Volume 190:Issue 3(2021)
• Page Start: 376
• Page End: 385
• Publication Date: 2020-09-23
• Subjects: all-cause mortality -- anticancer drugs -- cardiovascular events -- metastatic colorectal cancer -- population-based registries; Epidemiology -- Periodicals; Public health -- Periodicals; 614.4
• DOI: 10.1093/aje/kwaa203
• Languages: English
• ISSNs: 0002-9262

Abstract

Abstract: We aimed to investigate the association between use of anticancer drugs and cardiovascular-related hospitalization (CVRH) among patients with metastatic colorectal cancer (mCRC). A cohort study, the Anticancer Vigilance of Cardiac Events (AVOCETTE) Study, was conducted using data from the digestive tumor registry of a French county, the Département du Calvados. Incident mCRC cases diagnosed between 2008 and 2014 were included. The follow-up end date was December 31, 2016. Data from the county hospital center pharmacy and medical information departments were matched with the registry data. A competing-risks approach was used. Statistical tests were 2-sided. A total of 1, 116 mCRC patients were included, and they were administered 12, 374 rounds of treatment; fluorouracil, oxaliplatin, irinotecan, and bevacizumab were most common drugs used. A total of 208 CVRH events occurred in 145 patients (13.0%). The International Cancer Survival Standards type 1 standardized incidence was 84.0 CVRH per 1, 000 person-years (95% confidence interval: 72.6, 95.5). Anticancer drugs were not associated with a higher incidence of CVRH. Male sex, increasing age, a prior history of CVRH, and a higher Charlson comorbidity index score were associated with a higher incidence of CVRH. CVRH was significantly associated with higher all-cause mortality (multivariable hazard ratio = 1.58, 95% confidence interval: 1.28, 1.95). In this study, anticancer drugs were not associated with a higher incidence of CVRH in mCRC patients.